OUTCOMES OF BOTULINUM TOXIN TREATMENT FOR CHRONIC IDIOPATHIC CHILDHOOD CONSTIPATION

Ahmed Suliman, Hemanshoo Thakkar, Katherine de Rome, Alireza Keshtgar
Evelina Children's Hospital, Guy's and St. Thomas's NHS Foundation Trust, London, UK

Aim: Botulinum toxin (BT) is a well-recognised treatment of intractable constipation refractory to medical treatment. The aims of this study were to assess the short and long-term outcomes of BT injection into the external anal sphincter muscles (EAS) for treatment of chronic idiopathic constipation (CIC) in children.

Methods: All patients with CIC treated with BT were included from January 2009 to July 2016. We injected BT (Dysport®, Ipsen Ltd) 12 units/kg (maximum 200 units) in divided doses into the EAS muscles under endosonography guidance at 3 and 9 o'clock positions. Patients had anorectal manometry and colonic transit and their demographics, co-morbidities and symptoms were recorded. Parents were asked to complete a validated Symptom Severity (SS) questionnaire pre-operatively and at 3 months and 12 months follow up. The scores included eight domains with the sum of the scores ranging from 0(best) to 65(worst). A follow-up telephone call was made to assess longer-term outcomes. Statistical analysis of data was performed using the Wilcoxon signed rank test and data presented as median (range). P-value of <0.05 was considered significant.

Main Results: 103 patients underwent treatment with BT during the study period. The median age at presentation was 7 years (2-15.5 years). 56 (54%) patients were male and 31 (30%) had behavioural co-morbidities. The pre-operative SS score improved significantly from median 32(13-53) to 22 (0-45) at 3 months follow up, p<0.05. The improvement in SS score was maintained at 12 months follow up, 13 (0-48), p<0.05. 20 (19%) patients required formation of an antegrade continence enema (ACE) stoma.

Conclusions: Botulinum toxin injection into the external anal sphincter muscles is an effective treatment of children with intractable constipation not responding to conventional treatment. In our experience 81% of patients responded to BT treatment.